The research team led by Yoshiki Taniguchi of the Yokohama City University in Japan succeeded in making human iPS cells (inducible pluripotent stem cells) a miniature human that can function in mice and set a world precedent. The research team is scheduled to conduct clinical research within seven years and expects to use it for the treatment of childhood diseases within ten years. The results of this research were published in the British scientific journal on the 3rd day. 3D Printing,Custom Stereolithography,Custom 3D Printing,3D Print Services Suzhou FCE precision electronics Co., LTD , https://www.fukeyifcesz.com
The use of iPS cells for the production of hepatocytes has long resulted in certain achievements in various countries, but it is difficult to produce three-dimensional structures that can function. Taniguchi Hideki and Takayuki Takuya and other senior officials of the Yokohama City Research Team used iPS cells to cultivate pre-formation precursor cells, and then mixed mesenchymal cells with connective cells, and blood vessel-forming vascular endothelial cells, totaling about one million. Approximately four and eighteen hours later, they aggregated into a spherical structure of approximately five millimeters, similar to the seeds seen in the fetus, and then implanted in experimental mice.
After the blood vessels were connected, the seeds grew and possessed functions such as protein synthesis and agent metabolism. After the rats were transplanted for one month, the survival rate was increased from 30% to 90%.
The research team believes that humans may also be able to treat several small transplants. However, man-made must use the therapeutic function, it must transplant the patient's original three-size component at a time, because it must be hundreds to thousands of times more than the mini-cells.